Jun 11, 2020 / 07:00PM GMT
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VP
Good afternoon. Thanks for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs. And we're pleased to have Iovance Biotherapeutics with us. We have Maria Fardis, President and CEO here. And with that, Maria, thanks for joining us.
Questions and Answers:
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VPAnd to start, adoptive cell therapy is a rapidly expanding field. And can you just talk about your choice of using TILs to target cancer? And how this is differentiated, I guess, from the other approaches that we're seeing with CAR Ts, TCRs and some of the others? And are there particularly -- particular indications here that you see as more appropriate to be addressed with TILs? Or do you see -- and where do you see widespread potential of this modality? Lots of questions in one.
Maria Fardis - Iovance Biotherapeutics, Inc. - CEO, President & Director
Thank you, Salveen. Can I confirm you can
Trustpilot
